Thus, understanding the underlying molecular mechanisms of the crosstalk between these two proteins in response to chemotherapy in mutant-p53 GBM cells can shed light on the possibility of using Nrf2 inhibitors/activators to improve GBM treatment [15,16]. This evidence concerns the gene NFE2L2 and glioblastoma.